|
US7309687B1
(en)
|
1999-04-13 |
2007-12-18 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
|
|
US7345019B1
(en)
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
|
US6531121B2
(en)
|
2000-12-29 |
2003-03-11 |
The Kenneth S. Warren Institute, Inc. |
Protection and enhancement of erythropoietin-responsive cells, tissues and organs
|
|
PA8536201A1
(es)
|
2000-12-29 |
2002-08-29 |
Kenneth S Warren Inst Inc |
Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
|
|
EP1465987B1
(en)
|
2001-12-07 |
2008-01-23 |
Crucell Holland B.V. |
Production of viruses, viral isolates and vaccines
|
|
JP4865539B2
(ja)
|
2003-05-09 |
2012-02-01 |
クルセル ホランド ベー ヴェー |
Ｅ１不死化細胞の培養物及び該培養物を培養して該培養物から得られる産物の収量を増加させる方法
|
|
US20090311247A1
(en)
*
|
2005-01-25 |
2009-12-17 |
Apollo Life Sciences Limited |
Molecules and chimeric molecules thereof
|
|
PT1973559E
(pt)
|
2005-11-23 |
2013-02-19 |
Acceleron Pharma Inc |
Antagonistas de activina-actriia e utilizações para promover o crescimento ósseo
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
WO2007060213A2
(en)
*
|
2005-11-24 |
2007-05-31 |
Laboratoires Serono S.A. |
Erythropoietin polypeptides and uses thereof
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
CN103920139B
(zh)
|
2007-02-01 |
2018-02-02 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
|
|
TW201940502A
(zh)
|
2007-02-02 |
2019-10-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
TWI667038B
(zh)
|
2007-02-09 |
2019-08-01 |
美商艾瑟勒朗法瑪公司 |
包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
|
|
US7960343B2
(en)
|
2007-09-18 |
2011-06-14 |
Acceleron Pharma Inc. |
Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
TWI748373B
(zh)
|
2008-08-14 |
2021-12-01 |
美商艾瑟勒朗法瑪公司 |
使用gdf阱以增加紅血球水平
|
|
CN102482339B
(zh)
|
2009-06-08 |
2015-06-17 |
阿塞勒隆制药公司 |
用于增加产热脂肪细胞的方法
|
|
KR20210034684A
(ko)
|
2009-06-12 |
2021-03-30 |
악셀레론 파마 인코포레이티드 |
절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
|
|
JP6267425B2
(ja)
|
2009-11-17 |
2018-01-24 |
アクセルロン ファーマ， インコーポレイテッド |
筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
|
|
KR20130132824A
(ko)
|
2010-11-08 |
2013-12-05 |
악셀레론 파마 인코포레이티드 |
Actriia 결합제 및 이의 용도
|
|
CA2869674A1
(en)
|
2012-06-08 |
2013-12-12 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
MX389254B
(es)
|
2012-11-02 |
2025-03-20 |
Celgene Corp |
Antagonistas de activina-actrii y usos para tratar trastornos oseos y otros.
|
|
AP2017009674A0
(en)
|
2014-06-13 |
2017-01-31 |
Acceleron Pharma Inc |
Methods and compositions for treating ulcers
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
ES2946160T3
(es)
|
2014-12-03 |
2023-07-13 |
Celgene Corp |
Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
|
|
CN110144010B9
(zh)
*
|
2018-02-14 |
2021-01-05 |
上海洛启生物医药技术有限公司 |
阻断型pd-l1驼源单域抗体及其用途
|